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Abstract
Objective To investigate change inmental health after smoking cessation
compared with continuing to smoke.
Design Systematic review and meta-analysis of observational studies.
Data sourcesWeb of Science, Cochrane Central Register of Controlled
Trials, Medline, Embase, and PsycINFO for relevant studies from
inception to April 2012. Reference lists of included studies were hand
searched, and authors were contacted when insufficient data were
reported.
Eligibility criteria for selecting studies Longitudinal studies of adults
that assessed mental health before smoking cessation and at least six
weeks after cessation or baseline in healthy and clinical populations.
Results 26 studies that assessed mental health with questionnaires
designed to measure anxiety, depression, mixed anxiety and depression,
psychological quality of life, positive affect, and stress were included.
Follow-up mental health scores were measured between seven weeks
and nine years after baseline. Anxiety, depression, mixed anxiety and
depression, and stress significantly decreased between baseline and
follow-up in quitters compared with continuing smokers: the standardised
mean differences (95% confidence intervals) were anxiety −0.37 (95%
confidence interval −0.70 to −0.03); depression −0.25 (−0.37 to −0.12);
mixed anxiety and depression −0.31 (−0.47 to −0.14); stress −0.27 (−0.40
to −0.13). Both psychological quality of life and positive affect significantly
increased between baseline and follow-up in quitters compared with
continuing smokers 0.22 (0.09 to 0.36) and 0.40 (0.09 to 0.71),
respectively). There was no evidence that the effect size differed between
the general population and populations with physical or psychiatric
disorders.
Conclusions Smoking cessation is associated with reduced depression,
anxiety, and stress and improved positive mood and quality of life
compared with continuing to smoke. The effect size seems as large for
those with psychiatric disorders as those without. The effect sizes are
equal or larger than those of antidepressant treatment for mood and
anxiety disorders.
Introduction
Tobacco is the leading global cause of preventable death,
estimated to cause more than five million deaths a year, and
this is predicted to rise.1 The worldwide cost of healthcare from
tobacco use has been estimated within the billion dollar range.2
Smoking is a major risk factor for the development of cancers
and cardiovascular and respiratory diseases3; stopping smoking
substantially reduces these health risks.4 5 The association
between smoking and mental health, however, is less clear cut.
Although most smokers report wanting to quit,6 many continue
as they report that smoking provides them with mental health
benefits. Both quantitative and qualitative analyses indicate that
regular smokers report smoking cigarettes to alleviate emotional
problems and feelings of depression and anxiety, to stabilise
mood, and for relaxation as well as relieving stress.7-13 This
pattern of behaviour occurs in smokers with and without
diagnosed mental disorders.9-13 Unsurprisingly, views about
smoking predict whether or not people attempt to quit14 and
whether or not they are successful.15
Although smokers think that smoking offers mental health
benefits, there is a strong association between smoking and poor
mental health, and smokers with mental health disorders tend
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to be heavier smokers and more dependent.16 17 Three broad
explanations have been proposed to explain these associations:
smoking and poor mental health might have common causes18;
people with poor mental health smoke to regulate feelings such
as low mood and anxiety19; or smoking might cause or
exacerbate mental health problems.20 Although smokers with
andwithout mental disorders think that smoking providesmental
health benefits, they might be misattributing the ability of
cigarettes to abolish nicotine withdrawal as a beneficial effect
on mental health. Smokers experience irritability, anxiety, and
depression when they have not smoked for a while,21 22 and these
feelings are reliably relieved by smoking20 thus creating the
perception that smoking has psychological benefits, while in
fact it is smoking that caused these psychological disturbances
in the first place.
Whatever the cause, the association between smoking and poor
mental health warrants attention. Smokers might be less likely
to stop if they believe their mental health will suffer, and health
professionals might be reluctant to intervene with some smokers
because they believe that this might be detrimental to their
mental health.23 24 As a result, people with mental health
disorders have a life expectancy eight years less than the general
population,25 and much of this difference could be because of
smoking.17 For these reasons, we conducted a systematic review
and meta-analysis of observational data to examine the
difference in change in mental health between people who stop
smoking and people who continue to smoke. Our hypothesis
was that smokers who gave up would experience an
improvement in mental health as a result because they would
no longer experience multiple episodes of negative affect
induced by withdrawal.
Methods
This study followed PRISMA26 and MOOSE reporting
guidelines.27 There was no previously published protocol.
Eligibility criteria
We used broad eligibility criteria to capture all potentially
relevant data and then used sensitivity and subgroup analyses
to investigate clinical and methodological heterogeneity.
Eligibility was decided on based on the following criteria:
• Population—studies of smokers in the general population
or any that had selected smokers from populations defined
by the presence of a clinical diagnosis
• Exposure—studies that reported data on those who had
continued smoking and those who had quit smoking during
the study period
• Outcome—any study that had measured mental health
immediately before quitting and at least six weeks after
quitting.
• Language—no exclusions were made based on language
• Study design— only longitudinal studies (that is,
randomised controlled trials and cohort studies).
When data on change in mental health were available from
different follow-ups within a single study we took the longest.
Any type of measure of mental health was included (such as
self report and clinician scored). We included studies that
provided sufficient data to calculate the standardised mean
difference (SMD) and its variance in change in mental health
score from baseline to follow-up between quitters and continuing
smokers. The standardised mean difference is the difference in
change in mental health between baseline and follow-up divided
by the standard deviation (SD) of the change. It is used to
overcome the issue that depression, for example, can be
measured by different questionnaires with different scoring
systems. The questionnaires all measure depression but the
different scoring means that they cannot be combined by using
a simple mean. An SMD of 1 represents a difference in change
in depression score of 1 SD. About 4 SD encompasses 95% of
the population.28
Information sources and searches
We used searched Web of Science, Cochrane Central Register
of Controlled Trials, Medline, Embase, and PsycINFO for
studies published from inception to April 2012. We contacted
study authors to obtain relevant missing data. We also searched
reference lists of included studies. All non-English language
studies were translated.
We used a combination of text words and indexed terms related
to “mental health,” “smoking cessation,” and “smoking
reduction” (see appendix 1).
Study selection
Our aim was to maximise sensitivity by including studies in
initial screens even if data directly relevant to our question were
not presented in the abstract. One researcher screened titles of
retrieved studies for eligibility. The abstracts of eligible titles
were screened twice for inclusion. The researchers met after
independently screening abstracts to discuss inclusion/exclusion
of each article. If there were disagreements, two researchers
obtained and read the full text article.
Data collection process
Two researchers piloted the data extraction form, and appropriate
changes were then made. The same two researchers
independently extracted data from each paper and agreed on
final data extraction in the case of disagreement. The
corresponding authors of studies were contacted for additional
data when necessary. Studies were excluded only if we could
not obtain data on the change in mental health and its variance.
Data items
Participants—We recorded tobacco dependence and number
of cigarettes smoked a day, age, sex, and motivation to quit, all
at baseline.
Exposure—We extracted data on classification and
bioverification of abstinence.
Comparator—The same data items were extracted for
continuing smokers.
Outcomes—We extracted data on the change in mental health
between baseline and follow-up. When such data were not
available, we extracted data to calculate this (see statistical
methods). To categorise the mental health outcomes we
examined each measure’s key reference and questionnaire to
determine what it was designed to measure. We extracted the
change inmental health unadjusted for confounding and adjusted
for confounding using multivariable techniques.
Other items—We also extracted additional data to investigate
clinical and methodological heterogeneity within and across
studies (see sensitivity analyses for justification and methods).
These items included study design, study quality score
(Newcastle-Ottawa scale29), evidence of outcome reporting bias,
follow-up length, covariates adjusted for, mental health
management used in the intervention, and number of participants
analysed at baseline and follow-up.
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Statistical methods
Data extraction
The summary measure was the standardised mean difference
(SMD) in change in mental health from baseline to follow-up
between continuing smokers and people who managed to stop.
Some studies reported either the difference in change or the
standardised difference in change between continuing smokers
and quitters, and hence data extraction of the effect estimate
was straightforward. In some cases, studies presented the mean
change for each group and we calculated the differences. In
other cases, studies reported the mean at baseline and at
follow-up for each group.We calculated change and its variance
using a standard formula,30 imputing a correlation coefficient
taken from one of the largest studies included in the review (see
appendix 1). In all cases, we also extracted the variance. If the
variance was not presented we calculated it from P values,
confidence intervals, or F values following standard formula as
recommended by the Cochrane Collaboration.28
Meta-analysis method
We used a generic inverse variance random effects model to
pool the standardised mean difference (SMD) between change
in mental health in quitters and continuing smokers, from
baseline to follow-up. We chose a random effects model as it
incorporates heterogeneity both within and between studies.
Statistical heterogeneity was assessed with τ2 and I2 tests. We
used RevMan5 to conduct the meta-analyses and sensitivity and
subgroup analyses.
Studies’ effect estimates (SMD) were pooled by using the
following outcome categories: anxiety, depression, mixed
anxiety and depression, positive affect, psychological quality
of life, and stress. We used SMD because the scales used to
measure each outcome varied within category. This is standard
practice for meta-analyses as outlined within the Cochrane
Collaboration Handbook of Systematic Reviews and
Meta-Analyses,28 and as used in other high quality meta-analyses
of continuous mental health outcomes.31-33
We also combined studies with different follow-up periods.We
combined each study’s longest follow-up period, as suggested
by the Cochrane Collaboration. Heterogeneity between studies’
follow-up length was accounted for by use of a random effects
model. This is standard practice as outlined by the Cochrane
Collaboration,28 and as used in other high-quality meta-analyses
of continuous mental health, with varying follow-up periods.31-33
Quality assessment
We assessed the quality of the evidence in each study on the
association of change in smoking status with change in mental
health using the Newcastle-Ottawa quality scale,29 adapted for
this study (see appendix 1). This assesses the quality of evidence
based on the selection of the comparison groups, the
comparability of the groups, and the quality of the measurement
of exposure and outcome. The adapted scale rated studies from
0 to 5, and we deemed studies with a rating of 3 or lower as at
higher risk of bias.
Assessment of publication and outcome
reporting bias
We examined funnel plots for evidence of asymmetry and
conducted Egger tests for evidence of small study bias using
Stata 13.34
In some studies, data on change in mental health were presented
incidentally and the aim was to report on other data. In others,
the aim of the report was to present data on change in mental
health, therefore the decision to publish might have been
contingent on the results.We compared effect estimates between
studies in which mental health was the primary outcome and
those in which it was not to assess if there was evidence of
publication bias.
When studies had relevant data on change in mental health but
did not report sufficient data for meta-analysis, we attempted
to estimate the direction of association and compare this with
those included as this could indicate reporting bias.
Sensitivity analyses and assessment of risk
of bias within and across studies
We conducted multiple sensitivity analyses to examine if the
pooled effect estimate was influenced by including studies in
which the risk of bias was greater or was influenced by
characteristics of the study design or population. We either
performed subgroup analyses or removed studies presenting a
risk of bias and compared the pooled estimates with and without
the excluded studies.
Adjustment for covariates
It is possible that change in mental health could be confounded
by other differences between continuing smokers and quitters.
To account for this, some studies adjusted their data for
covariates thought to be associated with change in smoking
status. We conducted a subgroup analysis to compare the effect
estimate between studies that presented adjusted and unadjusted
data.
Loss to follow-up
Some studies reported on change in mental health only in
participants who were followed up, thus eliminating from the
analysis those who were lost-to-follow-up. Other studies
reported data on all participants who were present at baseline
and the smaller number present at follow up; thus possibly
creating spurious changes in mental health through loss to
follow-up. The convention in smoking cessation studies is to
regard participants who are lost to follow-up as smokers, so loss
to follow-up selectively affects the continuing smoker group.
We recorded whether or not studies reported data from a
different number of participants at baseline and follow-up.
Ascertainment of smoking status
Some studies might misclassify exposure by using point
prevalence smoking abstinence. This could include participants
who had been abstinent for only a week in the group we classed
as having been abstinent for at least six weeks, though most
smokers who are point prevalent abstinent for a week have in
truth been abstinent for longer.35 36 Recently abstinent smokers
are likely to experience withdrawal symptoms including low
mood.16 Thus, we recorded whether studies used a measure of
prolonged or continuous abstinence (when misclassification
could not have occurred) or if they used a point prevalence
measure of abstinence. Likewise, particularly in smoking
cessation trials, there is a danger that participants claim
abstinence when this is not the case; therefore it best practice
to bioverify smoking status.35Accordingly, we recorded whether
or not self reported abstinence was biologically verified.
Motivation to quit
Our hypothesis was that cessation improved mental health, but
our outcome measure was the difference in change in mental
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health between those who stopped smoking and those who
continued. It could be that such a difference would be evident
if those who continued smoking had a worsening in mental
health rather than those who stopped experiencing an
improvement. Trying and failing to quit could worsen mental
health, and some studies in the review derived data from
smoking cessation trials. In these trials, all continuing smokers
had tried but failed to achieve abstinence, and this
disappointment could lead to worse mental health. In population
cohorts, however, many continuing smokers would not have
tried to achieve abstinence and therefore not have experienced
this failure. We therefore classified studies as selected or not
selected bymotivation to quit. Populations in which participants
were not selected by motivation to quit were less likely to create
this spurious difference between quitters and continuing
smokers.
Psychotherapeutic component within cessation
intervention
Having a psychotherapeutic intervention can improve mental
health. Some smoking cessation interventions include mood
management. Successful quitters often attend smoking cessation
clinics, while relapsers cease attending, meaning that one group
might have had more counselling than the other. We searched
for the trial protocols and main report of the outcomes of all
smoking cessation intervention trials in which counselling had
taken place to assess whether mood management was part of
this.
Additional analyses
Clinical population comparison
The studies included in the review enrolled the general
population, pregnant women, or patients who were
postoperative, had a chronic physical condition, a psychiatric
condition, or chronic psychiatric or physical conditions. We
examined whether there was evidence of a difference in effect
size between these populations.
Study design
Our hypothesis was that stopping smoking improved mental
health but any association between cessation and improved
mood could be caused by reverse causation—that is, that
improved mood caused successful cessation. The studies in this
review fell into two groups: those recruiting a general population
of smokers and those in which all participants were enrolled in
smoking cessation trials. In trials, all participants attempted to
quit and therefore the decision to quit was not contingent on
mood. Secondary analyses from trials therefore exclude reverse
causation.
Length of follow-up
We also examined whether there was evidence of a difference
in effect estimate between studies in which change in mental
health was assessed from six weeks to six months or more than
six months after baseline.
Results
Study selection
The database and reference list searches resulted in 13 050
references. After initial screening we assessed 219 full text
articles for eligibility, of which 166 were excluded before data
extraction. Twenty seven were then excluded during data
extraction (see tables B and C in appendix 1 for details), 15 of
which provided sufficient descriptions to include in a narrative
synthesis of the direction and/or significance of change inmental
health. We included 26 studies in the meta-analyses and for six
of these studies authors supplied additional data (fig 1⇓) (the
full reference list is in appendix 1).
Outcome categories
The included studies examined six different measures of mental
health: anxiety, depression, mixed anxiety and depression,
positive affect, psychological quality of life, and stress (appendix
2).
Extraction
Several studies presented data on more than one outcome.
Sixteen effect estimates were calculated from groups’ mean
mental health scores, which were reported at both baseline and
follow-up. Seven were calculated from studies that presented
each groups’ mean change in mental health score from baseline
to follow-up. Two were calculated from a non-standardised
difference in change. Three were extracted from other types of
effect estimates.
Study characteristics
Eleven of the studies were cohort studies, 14 were secondary
analyses of cessation interventions, and one was a randomised
trial. Study enrolment included the general population (14
studies), populations living with a chronic physical condition
(three), pregnant women (two), postoperative patients (one),
people with either a chronic physical and/or psychiatric
condition (two), and people with psychiatric conditions (four).
The median age was 44, and on average 48% were men. On
average, participants smoked 20 cigarettes a day and scored 5.4
on the Fagerström test for nicotine dependence, indicating
moderate dependence. The median length of follow up was six
months (appendix 2 and 3).
In 11 studies, abstinence wasmeasured as continuous abstinence
from a point soon after baseline assessment, and in 18 studies
abstinence was biologically verified. In seven studies
participants received a psychological intervention as part of the
cessation intervention. In 17 studies participants were motivated
to quit (appendix 4).
Study quality
Twenty studies had high quality scores on the Newcastle-Ottawa
scale, and five had medium to low scores; for one study there
was insufficient information to determine a score (conference
abstract).
Results of meta-analyses
Anxiety
Four studies reported change in anxiety from baseline to
follow-up, with follow-ups ranging from seven weeks to 12
months (median six months). Compared with continuing to
smoke, quitting smoking was associated with a significant
decrease in anxiety from baseline to follow-up (standardised
mean difference (SMD) −0.37, 95% confidence interval −0.70
to −0.03; P=0.03). There was substantial statistical heterogeneity
between studies (I2=71%; fig 2⇓).28
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Mixed anxiety and depression
Five studies reported change in mixed anxiety and depression
from baseline to follow-up, with follow-up ranging from three
months to six years (median six months). Compared with
continuing to smoke, quitting smoking was associated with a
significant decrease in mixed anxiety and depression from
baseline to follow-up (SMD −0.31, 95% confidence interval
−0.47 to −0.14; P<0.001; I2=0%; fig 2⇓).
Depression
Ten studies reported change in depression from baseline to
follow-up, with follow-up ranging from 11 weeks to five years
(median 12 months). Compared with continuing to smoke,
quitting smoking was associated with a significant decrease in
depression from baseline to follow-up (SMD −0.25, 95%
confidence interval −0.37 to −0.12; P<0.001; I2=30%; fig 2⇓).
Stress
Three studies reported change in stress from baseline to
follow-up, with follow-up ranging from six months to six years
(median 12 months). Compared with continuing to smoke,
quitting smoking was associated with a significant decrease in
stress (SMD −0.27, 95% CI −0.40 to −0.13; P<0.001) from
baseline to follow-up (I2=0%; fig 2⇓).
Psychological quality of life
Eight studies reported change in psychological quality of life
from baseline to follow-up, with follow-ups ranging from two
months to nine years (median 12 months). Compared with
continuing to smoke, quitting smoking was associated with a
significant improvement in psychological quality of life from
baseline to follow-up (SMD 0.22, 95% confidence interval 0.09
to 0.36; P<0.001). There was moderate statistical heterogeneity
between studies (I2=63%; fig 3⇓).28
Positive affect
Three studies reported change in positive affect from baseline
to follow-up, with follow-ups ranging from three months to four
years (median 12months). Compared with continuing to smoke,
quitting smoking was associated with a significant increase in
positive affect from baseline to follow-up (SMD 0.40, 95%
confidence interval 0.09 to 0.71; P=0.01; I2=49%; fig 3⇓).
Sensitivity and subgroup analyses
We conducted numerous sensitivity and subgroup analyses to
investigate clinical and methodological heterogeneity and to
investigate risk of bias within and across studies.
Study quality
Removal of studies with medium to low scores on the
Newcastle-Ottawa scale did not greatly change the summary
estimates (table 1⇓).
Publication and outcome reporting bias
There were sufficient studies to create funnel plots for anxiety,
depression, mixed anxiety and depression, and psychological
quality of life. The plots were symmetrical for depression,
anxiety, and mixed anxiety and depression and asymmetrical
for psychological quality of life. Egger tests indicated that small
studies measuring psychological quality of life provided larger
effect estimates than studies with larger samples (P=0.017).
Seven out of eight of the pooled studies, however, had sample
sizes ranging from 34 to 323. Thus, the result of the Egger test
is likely influenced by the only large study (Sarna 2008, see
appendix 1), which analysed data from 11 809 participants, and
accounted for 25.7% of the pooled effect estimate. There was
no evidence of small study bias for studies that measured anxiety
(P=0.184), depression (P=0.064), mixed anxiety and depression
(P=0.307), positive affect (P=0.179), or stress (P=0.705).
In 20 of the 26 studies, the main aim was to report on change
in mental health and the decision to publish could have been
contingent on the strength or significance of the finding
(appendix 4). The main aim of the six other studies was to report
on other outcomes, and they reported only psychological quality
of life and positive affect. Subgroup analysis showed no
evidence of a difference in effect between studies that did not
primarily report on change in mental health and those that did
so for psychological quality of life (P=0.19) and positive affect
(P=0.14). One of the 26 studies showed evidence of multiple
testing and selectively reported the only significant result
(appendix 4).
Results of narrative synthesis
We excluded 15 studies because there were insufficient data to
extract an effect size or its variance, despite contact with the
authors (see table C in appendix 1). Nine of the 15 studies
reported on the significance of the difference in change between
quitters and continuing smokers (see table D in appendix 1):
three reported no significant difference, five favoured quitters,
and one study showed a difference favouring continuing
smoking. Of the nine studies, seven reported that mental health
improved in quitters, one showed no change, and one showed
a worsening in mental health for quitters. Five of nine studies
reported information on change in mental health for continuing
smokers; three studies reported that mental health had worsened
at follow-up and two reported that it had improved.
Adjustment for covariates
Two studies supplying estimates for three outcomes (anxiety,
depression, and positive affect) provided effect sizes of the
difference in change in mental health both unadjusted and
adjusted for confounders. The confounders included
demographics, information pertaining to tobacco consumption,
and/or treatment allocation. Comparison of these estimates
indicates that adjustment did not greatly change the results (table
2⇓).
We also compared the summary effect estimates from studies
that supplied only unadjusted effect estimates with studies that
supplied only adjusted effect estimates. Studies adjusted for
several potential confounders. For anxiety one study adjusted
for covariates, for depression four studies adjusted for covariates,
for psychological quality of life five studies adjusted for
covariates, for positive affect two studies adjusted for covariates,
and for stress and mixed anxiety and depression no studies
adjusted for covariates. The effect sizes were similar for studies
that did and did not adjust for covariates for all outcomes except
anxiety. Studies that adjusted for covariates showed a
significantly bigger difference between quitters and smokers
than those that did not adjust (table 3⇓).
Loss to follow-up
Twelve of the 26 studies reported means at baseline on a larger
number than contributed to the mean at follow-up. Removal of
these 12 did not greatly change the effect estimates (table 4⇓).
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Ascertainment of smoking status
Eleven studies did not report continuous abstinence,
classification of smoking status was not clear in four studies,
and eight did not biochemically confirm abstinence; exclusion
of these did not change the results (table 5⇓).
Motivation to quit
In a subgroup analysis we compared the 16 studies in which
participants were all attempting to quit with the 10 studies in
which participants were not selected bymotivation to quit. There
was no evidence of subgroup differences (table 6⇓, suggesting
that deterioration in mental health as a reaction to failing to quit
was an unlikely cause of the difference between quitters and
continuing smokers.
Psychotherapeutic component within cessation
intervention
Seven studies included a psychotherapeutic element in the
cessation intervention to help participants manage symptoms
of anxiety or lowmood. Removal of these studies did not greatly
change the summary estimate (table 7⇓).
Additional analyses
Comparison of clinical population
Fourteen studies enrolled smokers from the general population,
four enrolled patients with psychiatric disorders, three enrolled
patients with chronic physical conditions, two enrolled patients
with either psychiatric or physical conditions, two enrolled
pregnant women, and one enrolled patients after surgery. There
was no evidence that the effect size differed across these
different clinical populations (table 8⇓).
We were especially interested in the population with psychiatric
disorders, and data were available on change in depression,
mixed anxiety and depression, and positive affect. The effect
estimates for this subgroup compared with the general
populationwere −0.39 (95% confidence interval −0.63 to −0.14)
versus −0.30 (−0.48 to −0.12) for depression; −0.21 (−1.07 to
0.65) versus −0.32 (−0.53 to −0.11) for mixed anxiety and
depression; 0.40 (−0.03 to 0.83) versus 0.15 (−0.01 to 0.30) for
psychological quality of life; and 0.68 (0.24 to 1.12) versus 0.16
(−0.14 to 0.46) for positive affect.
Study design
Eleven studies were cohort studies, 14 were secondary analyses
of cessation interventions, and one was a randomised trial. There
was no evidence of subgroup differences between these study
designs (table 9⇓).
Length of follow-up
The effect sizes were similar for studies that assessed mental
health between six weeks and six months and those with
follow-ups longer than six months (table 10⇓). We also ordered
studies according to follow-up length in forest plots (figures 2
and 32⇓), which indicated no clear chronological pattern in effect
estimates.
Discussion
There is consistent evidence that stopping smoking is associated
with improvements in depression, anxiety, stress, psychological
quality of life, and positive affect compared with continuing to
smoke. The strength of association is similar for both the general
population and clinical populations, including those with mental
health disorders. There is no evidence that methodological
heterogeneity or short comings explained these associations nor
is there substantial evidence of publication bias.
Strength of the study
The strengths of this study lay in the broad search terms that
we used to retrieve literature, including hand searching to avoid
missing available literature and also checking reference lists of
included studies. We also contacted authors and calculated data
from papers in which, in most cases, the data were not provided
in a directly usable form.
Inmost included studies, the quality of measurement of exposure
status—smoking—was adequate. Nearly half of the studies
reported prolonged or continuous abstinence that was
biologically verified; this removed the threat of misclassification
of exposure. Sensitivity analysis showed no evidence that studies
that assessed smoking in other ways could have altered the
results. Inclusion of such studies would, in general,
underestimate the true strength of the association. Likewise,
assessment of outcome was good, with participants completing
validated self reported mental health questionnaires before they
stopped smoking and at follow-up. Assessors were, in that sense,
blind to exposure status, and no study was set up primarily to
investigate change in mental health on cessation.
Confounding is usually a major threat to the validity of most
associations based on observational data. In this case, there was
limited scope for confounding because we compared change
within individuals between groups. Confounders associated
with mental health at baseline and at follow-up will not affect
the validity of association. Confounding will occur only if the
strength or direction of association changes between baseline
and follow-up and that change differs by exposure group
(quitters and continuing smokers). The latter case is not so
plausible. In support of this, adjustment for potential
confounders, which were mostly factors associated with
propensity to achieve cessation, had only small effects in the
studies that reported such data.We consider that the data within
each study are robust and the association is unlikely to arise
through bias or confounding.
The validity of the review rests on whether the search retrieved
appropriate literature. We aimed to retrieve a large number of
cohort studies that might have contained data, even when this
was not readily apparent. Doing so, we uncovered several studies
that would have been missed if we had confined the search to
studies that seemed to be about smoking cessation and mental
health. In all cases, the data were derived from secondary
analyses of studies investigating other hypotheses (for example,
secondary analyses of cessation interventions, population
cohorts). It could be that authors of similar studies analysed the
data in the same way but found no association so might have
chosen not to publish the data. We found one example when a
study reported quantitative data only for the significant (and
presumably stronger) association and did not report other
non-significant associations. Other studies that reported on the
association but not completely enough for us to assess
quantitatively, however, seemed to give similar results to those
in which the data were more clearly presented. Overall, we
found little evidence of publication bias, but this cannot be
excluded.
Possible interpretations
We believe that the data are valid and propose three possible
explanations for the association. The first is that smoking
cessation causes the improvement in mental health, the second
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is that improving mental health causes cessation, and the third
is that a common factor explains both improved mental health
and cessation. Observational data can never prove causality,
but almost all we know about the harms of smoking and the
benefits of cessation derive from observational studies as
randomised trials to examine this have insurmountable ethical
and practical difficulties.
Could a common factor explain both cessation and improved
mental health? This supposes that a single factor—such as
positive life events—can cause people to attempt or achieve
cessation and improve mental health. As far as we know, there
is no evidence that positive life events lead to sustained
cessation. In addition, mental health outcomes were assessed
anywhere from seven weeks to nine years after baseline, and it
seems implausible that such events are associated with positive
mental health changes during this entire period.
An obvious explanation for the association is that improvements
in mental health prompt people to attempt cessation and that
this explains the association. This is contradicted by the data,
however. Over half the studies were secondary analyses of
randomised trials. In these studies everyone attempted cessation
and therefore the decision to quit was not contingent on change
in mental health. Subgroup analyses that split data by whether
they were derived from such trials or from population cohorts
showed no evidence of a difference and a significant difference
in change in smokers who quit compared with those who
continued in the trial based analyses. Further data support the
notion that cessation improves mood. In some but not all of the
studies we could calculate the change in mental health in quitters
and continuing smokers, rather than just the difference in the
change as we have presented.We calculated the weightedmean
change for both groups, though formal statistical analysis was
not possible to compare groups (data available on request).
These data indicate little change in mental health from baseline
to follow-up in continuing smokers, while smokers who quit
showed reductions in adverse mental health symptoms and
improvements in positive affect and quality of life. One of the
studies in the review was a trial in which participants were
randomised to continue smoking or quit. Obviously adherence
to this instruction was not absolute, but analysis of the data by
trial arm showed a modest benefit of cessation compared with
continuing to smoke. The trial was not powered to detect this
difference and it was not significant, but it does provide further
evidence to support the notion that stopping smoking leads to
improvements in mental health.
Data from a systematic review of randomised trials support the
notion that cessation improves mental health. Banham and
Gilbody systematically reviewed eight trials of smoking
cessation interventions in people with severe mental illnesses.37
All trials that assessed psychological function typically used
several scales at multiple times. Most showed no difference
between active and control groups, but the two studies that
reported significant differences favoured the intervention groups.
Another study reported after this review randomised people
with serious mental illness to cessation support or usual care.
It showed that cessation support reduced readmissions for
worsening mental illness.38 These data do not directly estimate
the effect of cessation on mental health because most people
who were randomised to the intervention did not quit. But these
findings, in people with serious mental illness, support the
findings in our review that psychological outcomes improve on
cessation.
Possible mechanisms
The hypothesis that cessation improves mood is supported by
a plausible biological mechanism. Chronic tobacco smoking is
associated with neuroadaptations in nicotinic pathways in the
brain. Neuroadaptations in these pathways are associated with
occurrence of depressed mood, agitation, and anxiety shortly
after a cigarette is smoked.39-42 This is known as the withdrawal
cycle and is marked by fluctuations in a smoker’s psychological
state throughout the day40 41 and could worsen mental health.20
A study reported that the neurological functioning of quitters
returned to the same level as non-smokers by three weeks after
cessation,43 consistent with reports that withdrawal symptoms
abate after a few weeks.21 The misattribution hypothesis is that
smokers attribute these symptoms as arising from stress or poor
mental health and conclude from the ability of cigarettes to
ameliorate these symptoms that cigarettes improve mental
health.
Not all data, however, support this causal interpretation. An
epidemiological study exploiting mendelian randomisation
examined the causal link between current smoking and current
anxiety and depression.44 Although there was some evidence
that smoking causes anxiety, the results as a whole did not
support a causal link between smoking status and current mental
health problems. These data argue against the misattribution
hypothesis, whereby periods of psychological changes related
to withdrawal from smoking are eliminated by neurological
adaptation to permanent deprivation of nicotine.
If the associations we found in this review are causal then the
effect size is clinically important. Fournier and colleagues
meta-analysed trials of selective serotonin reuptake inhibitors
and estimated the effect size.45 For mild to severe depression
the effect estimates ranged from −0.17 to −0.11; this is lower
than the effect size for smoking cessation. A meta-analysis of
34 randomised controlled trials assessed the effect of
antidepressants on generalised anxiety disorder.46 These effect
estimates ranged from −0.23 (−0.43 to −0.13) to −0.50 (−0.77
to −0.23); this is similar to smoking cessation at −0.37. This
result is particularly important in view of our findings in patients
with psychiatric disorders. There was no evidence that the effect
size differed between population subgroups based on clinical
diagnosis, and the effect on depression, psychological quality
of life, and positive affect was significant in people who had
mental disorders. These data should reassure doctors treating
patients with mental illness that cessation is unlikely to
exacerbate their symptoms and might indeed be therapeutic.
We recommend that future studies investigating the association
between stopping smoking and change in mental health should
use statistical techniques that can strengthen the causal
inferences that could be drawn from observational research.
Propensity score matching can be used to balance the
distribution of baseline covariates that could influence
disposition to group membership (smoking status). In addition,
mendelian randomisation can be used as an instrumental variable
approach by using genes that have a common association with
change in mental health and smoking status.
Conclusions
Whether or not smoking cessation directly causes the observed
improvement in mental health, there are direct clinical
implications. Smokers can be reassured that stopping smoking
is associated with mental health benefits. This could also
overcome barriers that clinicians have toward intervening with
smokers with mental health problems. Furthermore, challenging
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the widely held assumption that smoking has mental health
benefits could motivate smokers to stop.
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What is already known on this topic
Many smokers want to stop but continue smoking as they believe smoking has mental health benefits
In addition, health professionals are reluctant to deal with smoking in people with mental disorders in case stopping smoking worsens
mental health
What this study adds
Smoking cessation is associated with an improvement in mental health in comparison with continuing to smoke
The effect estimates are equal or larger to those of antidepressant treatment for mood disorders
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Tables
Table 1| Effect of smoking cessation on mental health. Sensitivity analysis after removal of studies of low quality (medium-low scores on
Newcastle-Ottawa scale)
Standardised mean difference (95% CI)
No of studies excludedNo of studies includedOutcome Original effect estimateEffect estimate
−0.37 (−0.70 to −0.03)−0.37 (−0.70 to −0.03)04Anxiety
−0.25 (−0.37 to −0.12)−0.29 (−0.42 to −0.15)19Depression
−0.31 (−0.47 to −0.14)−0.36 (−0.58 to −0.14)14Mixed anxiety and depression
0.22 (0.09 to 0.36)0.17 (−0.02 to 0.35)44Psychological quality of life
0.40 (0.09 to 0.71)0.68 (0.24 to 1.12)21Positive affect
−0.27 (−0.40 to −0.13)−0.23 (−0.39 to −0.07)12Stress
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Table 2| Effect of smoking cessation on mental health. Comparison of unadjusted and adjusted estimates from studies in which both were
presented
Standardised mean difference (95% CI)
Outcome (measure)Covariates adjusted forStudy Adjusted estimateUnadjusted estimate
−0.58 (−1.00 to −0.16)−0.54 (−1.42 to 0.34)Beck’s depression inventoryBaseline CO expiration,
baseline nicotine withdrawal
score, treatment group
allocation
Blalock (2008)*
0.68 (0.24 to 1.12)0.59 (−0.29 to 1.47)Positive and negative affect
schedule (positive affect
subscale)
−0.74 (−1.00 to −0.48)−0.62 (−0.88 to −0.36)State trait anxiety inventory-6Age, nicotine dependence, and
daily cigarette consumption
McDermott (2012)†
*Blalock JA, Robinson JD, Wetter DW, Schreindorfer LS, Cinciripini PM. Nicotine withdrawal in smokers with current depressive disorders undergoing intensive
smoking cessation treatment. Psychol Addict Behav 2008;22:122-8.
†McDermott M, Marteau T, Hollands G, Hankins M, Aveyard P. Change in anxiety following successful and unsuccessful attempts at smoking cessation: cohort
study. Br J Psychiatry 2013;202:62-7. (Was in press in 2012.)
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Table 3| Effect of smoking cessation on mental health. Subgroup analysis with comparison of effect estimates between studies that did
and did not adjust for covariates
Test for subgroup
differences
Standardised mean difference (95% CI)
Outcome Unadjusted estimateAdjusted estimateOriginal estimate
χ²=4.40, P=0.04−0.34 (−0.61 to −0.07)
(4 studies)
−0.74 (−1.00 to −0.48)
(1 study)
−0.37 (−0.70 to −0.03)
(4 studies)
Anxiety*
χ²=3.49, P=0.062−0.15 (−0.27 to−0.03)
(7 studies)
−0.41 (−0.65 to −0.17)
(4 studies)
−0.25 (−0.37 to −0.12) (10 studies)Depression*
Not applicable−0.31 (−0.47 to −0.14)
(5 studies)
No data−0.31 (−0.47 to −0.14)
(5 studies)
Mixed anxiety and
depression
χ²=2.22, P=0.140.68 (0.24 to 1.12)
(1 study)
0.28 (−0.02 to 0.57)
(2 studies)
0.40 (0.09 to 0.71)
(3 studies)
Positive affect
χ²=0.01, P=0.920.22 (−0.13 to 0.57)
(3 studies)
0.24 (0.07 to 0.40)
(5 studies)
0.22 (0.09 to 0.36)
(8 studies)
Psychological quality of
life
Not applicable−0.27 (−0.40 to −0.13)
(3 studies)
No data−0.27 (−0.40 to −0.13)
(3 studies)
Stress
*Please note that for anxiety and depression some studies provided both adjusted and unadjusted estimates, so these were compared within corresponding
subgroup analysis.
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Table 4| Effect of smoking cessation onmental health. Sensitivity analysis with removal of studies in which different numbers of participants
were analysed at baseline and follow-up
Standardised mean difference (95% CI)
No of studies excludedNo of studies includedOutcome Original effect estimateEffect estimate
−0.37 (−0.70 to −0.03)−0.37 (−0.70 to −0.03)04Anxiety
−0.25 (−0.37 to −0.12)−0.30 (−0.67 to 0.07)73Depression
−0.31 (−0.47 to −0.14)−0.26 (−0.44 to −0.07)23Mixed anxiety and depression
0.40 (0.09 to 0.71)0.40 (0.09 to 0.71)03Positive affect
0.22 (0.09 to 0.36)0.18 (0.02 to 0.33)35Psychological quality of life
−0.27 (−0.40 to −0.13)−0.27 (−0.42 to −0.12)12Stress
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Table 5| Effect of smoking cessation on mental health. Sensitivity analyses after ascertainment of smoking status
Standardised mean difference (95% CI)
No of studies excludedNo of studies includedRemoved studies and outcome Original effect estimateEffect estimate
Smoking status not biochemically verified
−0.37 (−0.70 to −0.03)−0.37 (−0.70 to −0.03)04Anxiety
−0.25 (−0.37 to −0.12)−0.32 (−0.50 to −0.13)37Depression
−0.31 (−0.47 to −0.14 )−0.35 (−0.59 to −0.10)23Mixed anxiety and depression
0.22 (0.09 to 0.36)0.17 (−0.02 to 0.35)44Psychological quality of life
0.40 (0.09 to 0.71)0.68 (0.24 to 1.12)21Positive affect
−0.27 (−0.40 to −0.13)−0.23 (−0.39 to −0.07)12Stress
Point prevalence smoking status
−0.37 (−0.70 to −0.03)−0.51 (−1.04 to 0.03)12Anxiety
−0.25 (−0.37 to −0.12)−0.34 (−0.52 to −0.16)46Depression
−0.31 (-0.47 to -0.14 )-0.29 (-0.52 to -0.07)23Mixed anxiety and depression
0.22 (0.09 to 0.36)0.37 (0.07 to 0.67)71Psychological quality of life
0.40 (0.09 to 0.71)0.39 (−0.11 to 0.90)12Positive affect
−0.27 (−0.40 to −0.13)−0.27 (−0.42 to −0.12)12Stress
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Table 6| Effect of smoking cessation on mental health. Subgroup analysis with comparison of studies in which participants were motivated
or not motivated to quit
Test for subgroup differencesStandardised mean difference (95% CI)Population (No of studies)
Anxiety
—−0.37 (−0.70 to −0.03)Overall (4)
χ²=2.77, P=0.10−0.41 (−0.81 to −0.00)Motivated to quit (3)
−0.19 (−0.68 to 0.30)Not motivated to quit (1)
Depression
—−0.25 (−0.37 to −0.12)Overall (10)
χ²=1.16, P=0.28−0.31 (−0.53 to −0.09)Motivated to quit (6)
−0.17 (−0.30 to −0.05)Not motivated to quit (4)
Mixed anxiety and depression
−0.31 ( −0.47 to −0.14)Overall (5)
χ²=0.19, P=0.66−0.35 (−0.59 to −0.10)Motivated to quit (3)
−0.27 (−0.50 to −0.04)Not motivated to quit (2)
Psychological quality of life
—0.22 (0.09 to 0.36)Overall (8)
χ²=0.17, P=0.680.20 (0.03 to 0.38)Motivated to quit (4)
0.26 (0.04 to 0.49)Not motivated to quit (4)
Positive affect
—0.40 (0.09 to 0.71)Overall (3)
χ²=3.95, P=0.110.39 (−0.11 to 0.90)Motivated to quit (2)
0.47 (0.04 to 0.90)Not motivated to quit (1)
Stress
—−0.27 (−0.40 to −0.13)Overall (3)
χ²=0.74, P=0.39−0.23 (−0.39 to −0.07)Motivated to quit (2)
−0.36 (−0.61 to −0.11)Not motivated to quit (1)
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Table 7| Effect of smoking cessation on mental health. Sensitivity analysis after removal of studies with psychological component within
cessation intervention
Standardised mean difference (95% CI)
No of studies excludedNo of studies includedOutcome Original effect estimateEffect estimate
−0.37 (−0.70 to −0.03)−0.37 (−0.70 to −0.03)04Anxiety
−0.25 (−0.37 to −0.12)−0.15 (−0.26 to −0.03)46Depression
−0.31 (−0.47 to −0.14)−0.28 (−0.46 to −0.10)23Mixed anxiety and depression
0.22 (0.09 to 0.36)0.15 (−0.01 to 0.31)35Psychological quality of life
0.40 (0.09 to 0.71)0.47 (0.04 to 0.90)21Positive affect
−0.27 (−0.40 to −0.13)−0.27 (−0.40 to −0.13)03Stress
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Table 8| Effect of smoking cessation on mental health. Subgroup analysis with comparison of effect estimates between different clinical
populations
Test for subgroup differencesEffect estimate standardised mean difference (95% CI)Outcome and population (No of studies)
Anxiety
—−0.37 (−0.70 to −0.03)Overall
χ²=2.77, P=0.10−0.48 (−0.81 to −0.15)General (3)
−0.06 (−0.42 to 0.30)Pregnant (1)
Depression
—−0.25 (−0.37 to −0.12)Overall
χ²=5.86, P=0.053−0.30 (−0.48 to −0.12)General (5)
−0.39 (−0.63 to −0.14)Psychiatric condition (3)
−0.07 (−0.23 to 0.09)Pregnant (2)
Mixed anxiety and depression
—−0.31 (−0.47 to −0.14)Overall
χ²=0.08, P=0.96−0.32 (−0.53 to −0.11)General (3)
−0.21 (−1.07 to 0.65)Psychiatric condition (1)
−0.29 (−0.57 to −0.01)Chronic physical and/or psychiatric condition (1)
Psychological quality of life
—0.22 (0.09 to 0.36)Overall
χ²=5.25, P=0.250.15 (−0.01 to 0.30)General (3)
0.40 (−0.03 to 0.83)Psychiatric condition (1)
0.60 (0.17 to 1.03)Chronic physical and/or psychiatric condition (1)
0.16 (−0.11 to 0.43)Chronic physical condition (1)
0.62 (−0.27 to 1.51)Postoperative (1)
Positive affect
—0.40 (0.09 to 0.71)Overall
χ²=3.95, P=0.110.47 (0.04 to 0.90)Chronic physical and/or psychiatric condition (1)
0.16 (−0.14 to 0.46)General (1)
0.68 (0.24 to 1.12)Psychiatric condition (1)
Stress
—−0.27 (−0.40 to −0.13)Overall
χ²=0.51, P=0·48−0.32 (−0.52 to −0.12)General (2)
−0.22 (−0.40 to −0.04)Chronic physical condition (1)
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Table 9| Effect of smoking cessation on mental health. Subgroup with comparison of effect estimates between different study designs
Test for subgroup differencesEffect estimate standardised mean difference (95% CI)Study design *No of studies)
Anxiety
—−0.37 (−0.70 to −0.03)Overall
χ²=4.07, P=0.13−0.06 (−0.42 to 0.30)Cohort (1)
−0.19 (−0.68 to 0.30)Randomised controlled trial (1)
−0.57 (−0.93 to −0.21)Secondary analyses of cessation intervention (2)
Depression
—−0.25 (−0.37 to −0.12)Overall
χ²=5.15, P=0.08−0.12 (−0.25 to 0.01)Cohort (3)
−0.39 (−0.88 to 0.10)Randomised controlled trial (1)
−0.36 (−0.53 to −0.18)Secondary analyses of cessation intervention (6)
Mixed anxiety and depression
—−0.31 (−0.47 to −0.14)Overall
χ²=0.76, P=0.38−0.28 (−0.46 to −0.10)Cohort (3)
−0.51 (−0.99 to −0.03)Secondary analyses of cessation intervention (2)
Psychological quality of life
—0.22 (0.09 to 0.36)Overall
χ²=0.95, P=0.330.28 (0.08 to 0.48)Cohort (5)
0.15 (−0.04 to 0.33)Secondary analyses of cessation intervention (3)
Positive affect
—0.40 (0.09 to 0.71)Overall
χ²=2.22, P=0.140.28 (−0.02 to 0.57)Cohort (2)
0.68 (0.24 to 1.12)Secondary analyses of cessation intervention (1)
Stress
—−0.27 (−0.40 to −0.13)Overall
χ²=0.74, P=0.39−0.36 (−0.61 to −0.11)Cohort (1)
−0.23 (−0.39 to −0.07)Secondary analyses of cessation intervention (2)
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Table 10| Effect of smoking cessation on mental health. Subgroup analysis after comparison of effect estimates between studies with
follow-up periods from baseline to follow-up between six weeks to six months and studies with follow-ups from baseline to more than six
months
Test for subgroup differences
Standardised mean difference (95% CI)
Outcome >6 months6 weeks to <6 monthsOriginal estimate
χ²=0.00, P=0.95−0.37 (−0.72 to −0.02) (1 study)−0.35 (−0.83 to 0.12) (3 studies)−0.37 (−0.70 to −0.03)Anxiety
χ²=0.25, P=0.62−0.23 (−0.41 to −0.06) (5 studies)−0.18 (−0.31 to −0.05) (8 studies)−0.25 (−0.37 to −0.12)Depression*
χ²=0.34, P=0.56−0.27 (−0.50 to −0.04) (2 studies)−0.37 (−0.58 to −0.15) (4 studies)−0.31 (−0.47 to −0.14)Mixed anxiety and depression*
χ²=2.22, P=0.140.28 (−0.02 to 0.57) (2 studies)0.68 (0.24 to 1.12) (1 study)0.40 (0.09 to 0.71)Positive affect
χ²=0.36, P=0.920.23 (0.09 to 0.37) (8 studies)0.30 (0.15 to 0.44) (7 studies)0.22 (0.09 to 0.36)Psychological quality of life*
χ²=0.01, P=0.92−0.27 (−0.42 to −0.12) (2 studies)−0.25 (−0.58 to 0.08) (1 study)−0.27 (−0.40 to -0.13)Stress
*Please note some studies measured outcome at multiple follow-ups, so these were compared within corresponding subgroup analysis
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Figures
Fig 1 Flow and identification of studies to include in review of change in mental health after smoking cessation
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Fig 2 Difference between change in mental health outcomes (anxiety, mixed anxiety and depression, depression, stress)
from baseline to longest follow-up in people who stopped smoking or continued to smoke. Study by McDermott was in
submission during search
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Fig 3 Difference between change in mental health outcomes (positive affect, psychological quality of life) from baseline to
longest follow-up in people who stopped smoking or continued to smoke
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